^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    melphalan

    i
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    Apply
    Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (NCT06172296)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    04/19/2024
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    ALK • TERT • MYCN
    |
    cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane
    Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (NCT03126916)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    05/14/2018
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    MYCN
    |
    MYCN amplification
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane
    Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (NCT05457556)
    Phase 3
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/15/2023
    Primary completion :
    12/01/2027
    Completion :
    12/01/2027
    FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C
    |
    FLT3-ITD mutation
    |
    Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)
    Fluoroquinolone Resistance Prevalence Study (FRE) (NCT05824689)
    Phase N/A
    Hackensack Meridian Health
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/08/2022
    Primary completion :
    12/17/2024
    Completion :
    04/01/2025
    CD34
    |
    melphalan
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Stem Cell Transplantation for Patients With Multiple Myeloma (NCT01526096)
    Phase 1
    University of Chicago
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    07/12/2011
    Primary completion :
    09/12/2025
    Completion :
    09/12/2025
    IL2RA • CD4 • FOXP3 • ISG20
    |
    melphalan • Simulect (basiliximab) • plerixafor
    Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation (NCT03856216)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    10/28/2019
    Primary completion :
    03/31/2027
    Completion :
    03/31/2027
    CD22 • HLA-DRB1 • HLA-B • HLA-C
    |
    Rituxan (rituximab) • methotrexate • Besponsa (inotuzumab ozogamicin) • bendamustine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar)
    CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant (CNS-PHLAT) (NCT06687772)
    Phase 2
    Washington University School of Medicine
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    01/16/2025
    Primary completion :
    07/31/2027
    Completion :
    07/31/2029
    CD34
    |
    carmustine • melphalan • thiotepa
    Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma (NCT06245629)
    Phase N/A
    Uppsala University
    Recruiting
    Last update posted :
    11/28/2024
    Initiation :
    11/24/2024
    Primary completion :
    03/31/2025
    Completion :
    11/30/2025
    SLC1A5
    |
    bortezomib • bendamustine • melphalan
    Umbilical Cord Blood Transplantation From Unrelated Donors (NCT03016806)
    Phase 1
    University of Rochester
    Recruiting
    Last update posted :
    08/19/2024
    Initiation :
    06/01/2015
    Primary completion :
    06/01/2025
    Completion :
    06/01/2026
    FLT3 • KMT2A
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous
    UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma (TT4B) (NCT00734877)
    Phase 3
    University of Arkansas
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    07/01/2008
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    TP53
    |
    TP53 deletion
    |
    cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dexamethasone • thalidomide • melphalan
    AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders (NCT00547196)
    Phase N/A
    City of Hope Medical Center
    Completed
    Last update posted :
    06/14/2024
    Initiation :
    08/16/2005
    Primary completion :
    11/11/2009
    Completion :
    05/28/2024
    KMT2A • HLA-DRB1 • HLA-B
    |
    cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous
    A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation (TSCAN-001) (NCT05473910)
    Phase 1
    TScan Therapeutics, Inc.
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    11/01/2022
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    HLA-A
    |
    HLA-A*02 • HLA-A2 positive • HLA-A positive
    |
    melphalan • TSC-100 • TSC-101
    Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis (NCT06022939)
    Phase 3
    SWOG Cancer Research Network
    Not yet recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/01/2024
    Primary completion :
    07/29/2030
    Completion :
    10/29/2030
    CD34
    |
    Chr t(11;14)
    |
    bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection
    HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE) (NCT06001385)
    Phase 2
    Center for International Blood and Marrow Trans...
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    12/08/2023
    Primary completion :
    02/01/2026
    Completion :
    06/30/2026
    HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan
    Personalized NK Cell Therapy in CBT (NCT02727803)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    05/19/2016
    Primary completion :
    05/31/2025
    Completion :
    05/31/2025
    FLT3 • BCL2
    |
    FLT3 mutation
    |
    Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT02443077)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    10/12/2016
    Primary completion :
    05/10/2025
    Completion :
    05/10/2025
    MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1
    |
    CD79A mutation + CD79B mutation
    |
    Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (NCT03579875)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    11/13/2018
    Primary completion :
    01/01/2026
    Completion :
    01/05/2029
    HLA-DRB1 • HLA-B • HLA-C
    |
    Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous
    The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (NCT05436418)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    11/18/2022
    Primary completion :
    06/25/2027
    Completion :
    07/02/2027
    IGH • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCI-2017-01069) (NCT03192397)
    Phase 1/2
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    08/09/2017
    Primary completion :
    08/21/2023
    Completion :
    05/21/2027
    HLA-DRB1
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous
    Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma (NCT01163357)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    01/28/2011
    Primary completion :
    07/20/2019
    Completion :
    12/31/2024
    HLA-DRB1
    |
    Chr del(17p)
    |
    bortezomib • sirolimus • melphalan • fludarabine IV
    HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS) (NCT04904588)
    Phase 2
    Center for International Blood and Marrow Trans...
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    09/30/2021
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-DPB1 • HLA-C
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous
    High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2) (NCT04221035)
    Phase 3
    Gustave Roussy, Cancer Campus, Grand Paris
    Recruiting
    Last update posted :
    05/15/2024
    Initiation :
    11/05/2019
    Primary completion :
    11/01/2026
    Completion :
    11/01/2032
    MYCN • MYCL
    |
    MYCN amplification • MYCL amplification
    |
    cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dacarbazine • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • cyclophosphamide intravenous • vindesine
    MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb) (NCT03188172)
    Phase 2
    University of Leeds
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    09/28/2017
    Primary completion :
    10/01/2025
    Completion :
    05/31/2026
    CD34
    |
    lenalidomide • bortezomib • cyclophosphamide • Darzalex (daratumumab) • dexamethasone • melphalan • Neupogen (filgrastim)
    Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (UKALL14) (NCT01085617)
    Phase 3
    University College, London
    Active, not recruiting
    Last update posted :
    05/10/2024
    Initiation :
    12/01/2010
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    ABL1 • BCR • MYC
    |
    MYC translocation • Chr t(4;11)(q21;q23)
    |
    Rituxan (rituximab) • imatinib • cytarabine • cyclophosphamide • etoposide IV • vincristine • daunorubicin • melphalan • Oncaspar liquid (pegaspargase) • fludarabine IV • nelarabine • mercaptopurine • Kepivance (palifermin)
    Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas (NCT03187210)
    Phase 1/2
    Insel Gruppe AG, University Hospital Bern
    Suspended
    Last update posted :
    05/09/2024
    Initiation :
    09/01/2018
    Primary completion :
    11/02/2023
    Completion :
    11/30/2024
    TNFRSF8
    |
    cytarabine • Adcetris (brentuximab vedotin) • melphalan
    Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (NCT02728102)
    Phase 2
    National Heart, Lung, and Blood Institute (NHLBI)
    Completed
    Last update posted :
    05/07/2024
    Initiation :
    07/01/2016
    Primary completion :
    06/30/2020
    Completion :
    12/09/2022
    CD34
    |
    lenalidomide • melphalan • Leukine (sargramostim)
    Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    05/03/2024
    Initiation :
    12/06/2019
    Primary completion :
    02/11/2024
    Completion :
    02/01/2025
    HLA-DRB1 • HLA-B • HLA-C
    |
    melphalan • fludarabine IV
    A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (NCT04872595)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    04/18/2024
    Initiation :
    04/30/2021
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    TP53 • HLA-DRB1 • CD34 • CD4
    |
    TP53 mutation
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma (RV-MM-PI-0691) (NCT01729091)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/18/2024
    Initiation :
    06/10/2013
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    TP53
    |
    TP53 mutation
    |
    lenalidomide • melphalan • Empliciti (elotuzumab)
    Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (NCI-2018-03732) (NCT03786783)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/04/2019
    Primary completion :
    12/31/2021
    Completion :
    09/22/2024
    MYCN • IL6 • CXCL9
    |
    MYCN amplification • IL6 expression
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • cyclophosphamide intravenous • dexrazoxane
    Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults (NCT04530487)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/11/2024
    Initiation :
    08/19/2020
    Primary completion :
    05/09/2025
    Completion :
    05/09/2025
    HLA-DRB1 • HLA-B • HLA-C
    |
    etoposide IV • melphalan • fludarabine IV • thiotepa • cyclosporin A microemulsion
    Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Active, not recruiting
    Last update posted :
    04/10/2024
    Initiation :
    01/02/2019
    Primary completion :
    06/23/2020
    Completion :
    06/28/2024
    FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA
    |
    FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
    |
    cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)
    CD34+ Transplants for Leukemia and Lymphoma (NCT05565105)
    Phase 2
    Guenther Koehne
    Not yet recruiting
    Last update posted :
    04/09/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/01/2031
    Completion :
    06/01/2031
    CD34
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (NCT00544115)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    04/02/2024
    Initiation :
    10/16/2001
    Primary completion :
    03/13/2007
    Completion :
    12/30/2024
    HLA-DRB1 • HLA-B
    |
    cyclophosphamide • etoposide IV • sirolimus • melphalan • fludarabine IV • busulfan • cyclosporine • cyclophosphamide intravenous
    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors (NCT01804634)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/27/2024
    Initiation :
    03/27/2013
    Primary completion :
    01/01/2027
    Completion :
    01/01/2030
    HLA-DRB1 • HLA-DQB1 • HLA-B
    |
    cyclophosphamide • melphalan • fludarabine IV • cyclophosphamide intravenous
    Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma (NCT02342782)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/19/2024
    Initiation :
    06/08/2020
    Primary completion :
    09/18/2020
    Completion :
    12/31/2024
    ALK • CD34
    |
    cytarabine • etoposide IV • etoposide oral • carmustine • melphalan • Simulect (basiliximab)
    Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (NCT01476839)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/19/2024
    Initiation :
    11/09/2012
    Primary completion :
    07/24/2021
    Completion :
    12/31/2024
    CD34
    |
    cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab)
    Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (LYMA-101) (NCT02896582)
    Phase 2
    The Lymphoma Academic Research Organisation
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    10/01/2016
    Primary completion :
    03/01/2019
    Completion :
    03/01/2025
    CD20 • CCND1 • CD5
    |
    Chr t(11;14) • CD20 expression • CCND1 expression
    |
    cisplatin • cytarabine • Gazyva (obinutuzumab) • etoposide IV • dexamethasone • carmustine • melphalan
    Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (NCT01885689)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    02/10/2014
    Primary completion :
    12/27/2019
    Completion :
    12/30/2024
    HLA-B • HLA-C
    |
    sirolimus • clofarabine • melphalan
    CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma (NCT04690192)
    Phase 1/2
    Zou Dehui
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    01/01/2021
    Primary completion :
    12/30/2023
    Completion :
    12/30/2024
    BCL6
    |
    BCL6 rearrangement
    |
    gemcitabine • melphalan • busulfan • Yuanruida (inaticabtagene autoleucel)
    Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (NCT01798004)
    Phase 1
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    03/13/2024
    Initiation :
    04/08/2013
    Primary completion :
    07/28/2015
    MYCN
    |
    MYCN amplification • MYCN expression
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • busulfan • Neupogen (filgrastim) • cyclophosphamide intravenous